Current advances in giant cell arteritis

Kaushik, Megha; Ponte, Cristina; Mollan, Susan P

doi:10.1097/wco.0000000000000889

Cited by 4 publications

(6 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…die Hälfte der Patienten mit einer Riesenzellarteriitis über Beschwerden im Sinne einer Polymyalgie klagen, entwickelt nur jeder 5. PMR-Patient eine Riesenzellarteriitis [7,22]. Die Beteiligung der Aorta und ihrer Hauptäste bleibt dagegen vor allem initial asymptomatisch.…”

Section: Klinikunclassified

Riesenzellarteriitis

Ness,

Nölle

2024

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

ZusammenfassungDie Riesenzellarteriitis (RZA) ist die häufigste primäre Vaskulitis und geht mit potenziell bilateraler Erblindungsgefahr einher. Weder klinisch noch laborchemisch gibt es einen einfachen und eindeutigen Beweis für diese Erkrankung, die i. d. R. eine schnelle und sichere Diagnose und Therapie erfordert. Bei folgenden Augensymptomen sollte der Augenarzt an eine RZA denken: Sehverschlechterung oder Gesichtsfeldausfälle, vorübergehende Sehstörungen (Amaurosis fugax), Doppelbilder, Augenschmerzen sowie neu aufgetretene Kopf- oder Kauschmerzen. Es sollte umgehend eine augenärztliche Untersuchung mit Spaltlampe, Ophthalmoskopie und Gesichtsfeld sowie eine Farbduplexsonografie der A. temporalis erfolgen. Bei hinreichendem klinischem Verdacht auf RZA sollte unverzüglich unter Kortisontherapie eine zeitnahe Vorstellung beim Rheumatologen/Internisten und ggf. eine Temporalarterienbiospie organisiert werden. Zahlreiche Entwicklungen der modernen Bildgebung mit Farb-Duplex-Sonografie, MRT und PET-CT können mit der klassischen, bewährten Biopsie einer Temporalarterie konkurrieren. Eine frühzeitige Bestimmung von BSG und CRP kann die RZA-Diagnose untermauern. Therapeutisch kann eine steroidersetzende bzw. steroidreduzierende Immunsuppression mit IL-6-Blockade oder Methotrexat erwogen werden. Diese Entwicklungen haben zu einer Überarbeitung sowohl der Klassifikationskriterien als auch der Diagnostik- und Therapieempfehlungen von American College of Rheumatologists und European League against Rheumatism geführt, die hier für die Augenheilkunde zusammengestellt sind.

show abstract

Section: Klinikunclassified

Riesenzellarteriitis

Ness,

Nölle

2024

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

show abstract

“…Nearly half of people with GCA have symptoms of PMR (Fig. 2 ) while up to one-fifth of people with PMR will be diagnosed with GCA [ 5 , 42 ]. There may be large vessel involvement in cranial GCA, which may be asymptomatic and revealed by diagnostic imaging alone [ 45 , 46 ].…”

Section: Clinical Presentationmentioning

confidence: 99%

“…CLINICAL PRESENTATION GCA has heterogeneous clinical features due to the overlapping spectrum of the known clinical phenotypes: cranial GCA (C-GCA), large vessel GCA (LV-GCA), and polymyalgia rheumatica (PMR) (Fig. 2) [42]. The majority of people with cranial GCA will have symptoms of new onset headache, jaw claudication and cutaneous allodynia [8,43,44].…”

Section: Ageing Processes and Gcamentioning

confidence: 99%

Giant cell arteritis: reviewing the advancing diagnostics and management

Bilton

Mollan

2023

Eye

Self Cite

View full text Add to dashboard Cite

Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss. The immunopathophysiology has continued to be characterised, and the influencing of ageing in the development of GCA is beginning to be understood. Recent national and international guidelines have supported the directed use of cranial ultrasound to reduce diagnostic delay and improve clinical outcomes. Immediate high dose glucocorticoids remain the standard emergency treatment for GCA, with a number of targeted agents that have been shown in clinical trials to have superior clinical efficacy and steroid sparing effects. The aim of this review was to present the latest advances in GCA that have the potential to influence routine clinical practice.

show abstract

“…Giant cell arteritis (GCA) is caused by systemic granulomatous vasculitis that can affect any size of artery. 1 The incidence of GCA is approximately 1.2 per 10,000 people in the UK and nearly exclusively occurs in people over 50 years old, with the incidence significantly increasing with age. GCA is twice as common in women than men and most commonly affects people of Scandinavian descent.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, there is no specific accessible biomarker that can definitively diagnose GCA. 1 GCA is a medical emergency as it can lead to sudden, permanent blindness. [4][5][6] European guidance has recommended the firstline investigations of ultrasound of the temporal arteries.…”

Section: Introductionmentioning

confidence: 99%

An update on the clinical approach to giant cell arteritis

et al. 2022

View full text Add to dashboard Cite

Recent national and international guidance from rheumatology societies have reflected the advances in evidence for both the investigation and management of giant cell arteritis. Cranial ultrasound reduces diagnostic delay and improves clinical outcomes. Immediate high-dose glucocorticoids remain the standard treatment for giant cell arteritis. Randomised controlled trial evidence using tocilizumab, an interleukin-6 receptor antagonist, has been shown to have good clinical efficacy with glucocorticoid sparing effects. Overall patient outcomes appear to be improved by formalising pathways for diagnosis to include clinical experts' opinion early in decision making.

show abstract

Current advances in giant cell arteritis

Cited by 4 publications

References 75 publications

Riesenzellarteriitis

Riesenzellarteriitis

Giant cell arteritis: reviewing the advancing diagnostics and management

An update on the clinical approach to giant cell arteritis

Contact Info

Product

Resources

About